Expressive

rs11130207 - BSN

Magnitude 2.2 · 1 study on file

Reported associations

  • Translational genomics of osteoarthritis in 1,962,069 individuals - Unknown journal (n.d.) · Unknown authors · PubMed 40205036

    ABSTRACT: Osteoarthritis is the third most rapidly growing health condition associated with disability, after dementia and diabetes. By 2050, the total number of patients with osteoarthritis is estimated to reach 1 billion worldwide. As no disease-modifying treatments exist for osteoarthritis, a better understanding of disease aetiopathology is urgently needed. Here we perform a genome-wide association study meta-analyses across up to 489,975 cases and 1,472,094 controls, establishing 962 independent associations, 513 of which have not been previously reported. Using single-cell multiomics data, we identify signal enrichment in embryonic skeletal development pathways. We integrate orthogonal lines of evidence, including transcriptome, proteome and epigenome profiles of primary joint tiss

Auto-generated from study metadata. AI-synthesised commentary is added when this entry is regenerated through content-service's LLM mode.

Lifestyle context

Concrete actions anchored to the cited research. We do not prescribe, we describe.

Discuss with your doctor

  • Genetic risk for osteoarthritis Moderate

    Personalized risk assessment considering genetic and environmental factors enables targeted prevention strategy

Exercise

  • Regular joint-protective exercise Moderate

    Higher genetic predisposition to osteoarthritis can be partially offset by maintaining muscle strength and joint mobility

    150 minutes moderate-intensity weekly or equivalent low-impact activity

Lifestyle

  • Maintain healthy BMI Moderate

    Excess weight increases mechanical stress on joints, exacerbating osteoarthritis development in genetically predisposed individuals

    BMI 18.5-24.9, or discussion with provider for personalized target

Screening

  • Early screening for osteoarthritis signs Moderate

    Genetic risk increases probability of disease onset, making proactive screening valuable for early intervention

    Baseline assessment at age 40-50, then every 2-3 years or with symptom onset